Preferred Label : Laventatug Tivedotin;
NCIt synonyms : Anti-LIV-1/MMAE ADC BRY812; Anti-LIV-1 ADC BRY812; Anti-LIV-1 Antibody-drug Conjugate BRY812;
NCIt definition : An antibody-drug conjugate (ADC) composed of laventatug, a humanized monoclonal antibody
directed against solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1;
ZIP6) that is conjugated, via a linker, to the cytotoxic agent monomethyl auristatin
E (MMAE), with potential antineoplastic activity. Upon administration and binding
to LIV-1-positive tumor cells, laventatug tivedotin enters the tumor cell lysosome
through endocytosis, and releases MMAE. MMAE binds to and inhibits tubulin polymerization,
which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing
tumor cells. LIV-1, a multi-pass transmembrane protein and zinc transporter, is expressed
in several types of solid tumors and plays a key role in tumor cell progression, proliferation
and metastasis. The conjugation method and linkage system prevent MMAE from separating
from the antibody during circulation, thereby limiting off target toxicity.;
UNII : NUK386L57F;
CAS number : 3009829-96-0;
Molecule name : BRY-812; BRY 812;
NCI Metathesaurus CUI : CL1920700;
Origin ID : C201827;
UMLS CUI : C5907932;
Semantic type(s)
- concept_is_in_subset
- has_target
